Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Vaughn

Showing results (11-20 of 94) with videos related to

Pageof 10
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|March 7, 2002
West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacyAlexander G Pletnev, Robert Putnak, Jim Speicher, et al.
Vaccine|April 13, 2007
Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005Joachim Hombach, M Jane Cardosa, Arunee Sabchareon, et al.
The American Journal of Tropical Medicine and Hygiene|April 14, 2005
Characterization of dengue-2 virus binding to surfaces of mammalian and insect cellsButsaya K Thaisomboonsuk, Edward T Clayson, Somsak Pantuwatana, et al.
Human Vaccines & Immunotherapeutics|April 13, 2012
Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 yearsAkihiko Saitoh, Akira Nagai, Kazuyoshi Tenjinbaru, et al.
Journal of Biomedical Science|May 10, 2007
Characterization of monoclonal antibodies to hepatitis E virus (HEV) capsid protein and identification of binding activityJunkun He, Robert A Kuschner, Vincent Dewar, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|June 12, 2002
Clinical and immunological risk factors for severe disease in Japanese encephalitisDaniel H Libraty, Ananda Nisalak, Timothy P Endy, et al.
Journal of Virological Methods|July 6, 2004
Development and evaluation of an efficient 3'-noncoding region based SARS coronavirus (SARS-CoV) RT-PCR assay for detection of SARS-CoV infectionsHuo-Shu H Houng, David Norwood, George V Ludwig, et al.
NPJ Vaccines|October 29, 2021
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19Harry Kleanthous, Judith Maxwell Silverman, Karen W Makar, et al.
Vaccine|July 17, 2013
Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trialWilliam H Yang, Marc Dionne, Michael Kyle, et al.
Vaccine|May 11, 2011
Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 monthsGeorge Risi, Louise Frenette, Joanne M Langley, et al.
Pageof 10

Showing results (11-20 of 94) with videos related to

Sort By:
Pageof 10
Proceedings of the National Academy of Sciences of the United States of America|March 7, 2002
West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacyAlexander G Pletnev, Robert Putnak, Jim Speicher, et al.
Vaccine|April 13, 2007
Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005Joachim Hombach, M Jane Cardosa, Arunee Sabchareon, et al.
The American Journal of Tropical Medicine and Hygiene|April 14, 2005
Characterization of dengue-2 virus binding to surfaces of mammalian and insect cellsButsaya K Thaisomboonsuk, Edward T Clayson, Somsak Pantuwatana, et al.
Human Vaccines & Immunotherapeutics|April 13, 2012
Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 yearsAkihiko Saitoh, Akira Nagai, Kazuyoshi Tenjinbaru, et al.
Journal of Biomedical Science|May 10, 2007
Characterization of monoclonal antibodies to hepatitis E virus (HEV) capsid protein and identification of binding activityJunkun He, Robert A Kuschner, Vincent Dewar, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|June 12, 2002
Clinical and immunological risk factors for severe disease in Japanese encephalitisDaniel H Libraty, Ananda Nisalak, Timothy P Endy, et al.
Journal of Virological Methods|July 6, 2004
Development and evaluation of an efficient 3'-noncoding region based SARS coronavirus (SARS-CoV) RT-PCR assay for detection of SARS-CoV infectionsHuo-Shu H Houng, David Norwood, George V Ludwig, et al.
NPJ Vaccines|October 29, 2021
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19Harry Kleanthous, Judith Maxwell Silverman, Karen W Makar, et al.
Vaccine|July 17, 2013
Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trialWilliam H Yang, Marc Dionne, Michael Kyle, et al.
Vaccine|May 11, 2011
Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 monthsGeorge Risi, Louise Frenette, Joanne M Langley, et al.
Pageof 10